G. Dito

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

I. Melero, A. Korman, P. Fracasso, 2019, Clinical Cancer Research.

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

A. Korman, S. Dillon, M. Selby, 2017, Oncoimmunology.

Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in combination with ixabepilone in preclinical tumor models

F. Lee, M. Jure-Kunkel, G. Dito, 2008 .

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models

Maria Jure-Kunkel, J. Hunt, F. Lee, 2013, Cancer Immunology, Immunotherapy.

Assessment of tissue biomarkers following anti-CD137 treatment in the EMT-6 mouse tumor model.

D. Shuster, Z. Tsuchihashi, M. Jure-Kunkel, 2006 .

Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.

A. Korman, S. Dillon, M. Selby, 2013 .